Table 2.
Revised original diagnostic scoring system of the International Autoimmune Hepatitis Group in 1999
| No. | Clinical feature | Score | |
|---|---|---|---|
| 1 | Female | + 2 | |
| 2 | ALP/AST (or ALT) ratio | ||
| < 1.5 | + 2 | ||
| 1.5–3.0 | 0 | ||
| > 3.0 | − 2 | ||
| 3 | Serum globulin or IgG level above ULN | ||
| > 2.0 | + 3 | ||
| 1.5–2.0 | + 2 | ||
| 1.0–1.5 | + 1 | ||
| < 1.0 | 0 | ||
| 4 | ANA, SMA, or anti-LKM1 | ||
| > 1:80 | + 3 | ||
| 1:80 | + 2 | ||
| 1:40 | + 1 | ||
| < 1:40 | 0 | ||
| AMA positive | − 4 | ||
| 5 | Hepatitis markers | ||
| Positive | − 3 | ||
| Negative | + 3 | ||
| 6 | Hepatotoxic drug exposure | ||
| Positive | − 4 | ||
| Negative | + 1 | ||
| 7 | Average alcohol intake (g/day) | ||
| < 25 | + 2 | ||
| > 60 | − 2 | ||
| 8 | Histologic findings | ||
| Interface hepatitis | + 3 | ||
| Lymphoplasmacytic infiltrate | + 1 | ||
| Rosette formation | + 1 | ||
| None of the above | − 5 | ||
| Biliary changes | − 3 | ||
| Other atypical changes | − 3 | ||
| 9 | Concurrent other immune disease | + 2 | |
| 10 | Other autoantibodies | + 2 | |
| 11 | HLA DRB1*03 or DRB1*04 | + 1 | |
| 12 | Response to corticosteroids | ||
| Complete | + 2 | ||
| Relapse after drug withdrawal | + 3 | ||
| Aggregate score pretreatment | |||
| Definite AIH | > 15 | ||
| Probable AIH | 10–15 | ||
| Aggregate score posttreatment | |||
| Definite AIH | > 17 | ||
| Probable AIH | 12–17 | ||
ALP alkaline phosphatase, AST aspartate aminotransferase, ALT alanine aminotransferase, IgG immunoglobulin G, ULN upper limit of the normal range, HLA human leukocyte antigen, ANA antinuclear antibodies, SMA smooth muscle antibodies, anti-LKM1 antibodies to liver kidney microsome type 1, AMA antimitochondrial antibodies